CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

PD-1 blocking antibody+standard treatmentWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1163 Thymosin+standard treatment Wiki 1.00
drug1404 standard treatment Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.07
D018352 Coronavirus Infections NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.07

There is one clinical trial.

Clinical Trials

1 Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients

Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died. Studies in China also showed that more than 1 million patients died of sepsis in 2015. Previous studies have suggested that sepsis are often secondary to excessive inflammatory response syndrome. However, treatment measures targeting excessive inflammatory response failed to effectively improve the prognosis of patients. PD-1 and PD-L1 are key mediators in T cell depletion in sepsis patients. Therefore, the investigators try to performe a clinical research to investigate the efficacy of PD-1 and thymosin in patients with severe pneumonia associated with lymphocytopenia in 2019 novel coronavirus infection.

NCT04268537 2019 nCoV, PD-1 Drug: PD-1 blocking antibody+standard treatment Drug: Thymosin+standard treatment Other: standard treatment

Primary Outcomes

Description: proportion of lung injury score decreased 1 or more points

Measure: lung injury score

Time: 7 days

Secondary Outcomes

Description: lymphocyte counts at day 7, 14 and 28 after randimization

Measure: absolute lymphocyte counts

Time: 7, 14 and 28 days

Description: serum level of CRP, PCT and IL-6 at day 3,7 and 14 after randimization

Measure: serum level of CRP, PCT and IL-6

Time: 3, 7 and 14 days

Description: SOFA score at Day 7, with scores range from 0 to 24 and higher score means worse outcome

Measure: SOFA score

Time: 7 days

Description: died at day 28

Measure: all cause mortality rate

Time: 28 days

Measure: ventilation free days

Time: 28 days

Measure: ICU free days

Time: up to 28 days

No related HPO nodes (Using clinical trials)